FDA panel votes against ablation ultrasound treatment for prostate cancer

  • August 1, 2014

An FDA panel recently rejected a high-focus ultrasound device as a treatment for low-risk, localized prostate cancer.

The ultrasound system (Ablatherm-HIFU, EDAP Technology) is intended to treat prostate cancer by ablating the entire prostate gland via high intensity focused ultrasound, which generates heat of around 200 degrees Fahrenheit. Currently, there are no other high intensity focused ultrasound devices on the market.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
More»
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
HemOnc Today